Spyre Therapeutics (SYRE) was recently removed from several Russell Value benchmarks, a change that can influence trading as index funds adjust holdings and investors reassess the stock’s role in portfolios.

Spyre Therapeutics’ recent removal from several Russell Value benchmarks and the filing of a US$500 million follow on equity offering come after a sharp run, with the 90 day share price return of 74.25% and year to date share price return of 187.41% pointing to strong momentum despite a 12.39% pullback over the past week and a very large 1 year total shareholder return that contrasts with a much weaker 5 year total shareholder return.

If you are looking for other potential opportunities in healthcare related AI and data driven drug development, it is worth scanning the 40 healthcare AI stocks

With Spyre Therapeutics now outside key value indexes, a US$500 million at-the-market offering in place, no revenue yet and a market cap of about US$7.6b, is there still upside on the table, or is the market already pricing in future growth?

Preferred Price to Book Multiple of 14.8x: Is it justified?

On a simple yardstick, Spyre Therapeutics looks expensive, with a P/B of 14.8x against both the broader US Biotechs industry at 2.6x and a peer average of 13.3x.

The P/B ratio compares the company’s market value to its book value, which is essentially net assets on the balance sheet. For a pre revenue, loss making biotech like Spyre Therapeutics, a high P/B often reflects investor focus on the pipeline, trial progress and future optionality, rather than current financials.

With no revenue, a reported net loss of $148.703m and forecasts that Spyre Therapeutics will remain unprofitable over the next 3 years, the 14.8x P/B indicates that the market is assigning a premium valuation to its IBD and rheumatic disease pipeline and combination antibody programs. The contrast with the much lower industry average and peer multiple shows that a significant portion of the current $7.6b market value is tied to expectations about future clinical and commercial outcomes rather than existing earnings power.

Result: Price to book ratio of 14.8x

However, Spyre Therapeutics still faces meaningful risks, including clinical trial setbacks in its IBD and rheumatic programs and potential dilution from the US$500 million equity offering.

Next Steps

With sentiment mixed after Spyre Therapeutics’ sharp share price moves, index removal and premium P/B multiple, it makes sense to review the numbers yourself. If you want a clear view of the 1 or more risks investors are watching, start with the 5 important warning signs.

Looking for more investment ideas beyond Spyre Therapeutics?

If Spyre Therapeutics has sharpened your interest in focused stock research, do not stop here. Broaden your watchlist with other ideas that fit your style.

• Target dependable income potential by scanning companies we flag as yield standouts through the 8 dividend fortresses.
• Hunt for quality at a reasonable price by working through the 44 high quality undervalued stocks that focuses on fundamentals, cash flows and balance sheet strength.
• Spot opportunities others may be overlooking by checking the screener containing 19 high quality undiscovered gems, built to surface lesser known stocks with solid underpinnings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.